LSKL, Inhibitor of Thrombospondin TSP-1 2TFA

SKU: orb1299602

Description

LSKL (2TFA) is a small molecule inhibitor of thrombospondin-1 (TSP-1)-mediated activation of TGF-β. This compound is a valuable research tool for studying TGF-β signaling pathways in fibrosis, cancer, and wound healing models, both in vitro and in vivo.

Research Area

Pharmacology & Drug Discovery, Stem Cell & Developmental Biology

Key Properties

• MW: 686.64
• Purity: 99.75% (May vary between batches)
• Formula: C₂₅H₄₄F₆N₆O₉
• SMILES: CC(C)C[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@@H](N)CC(C)C)=O)=O)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O
• Target: TGF-beta/Smad
• Solubility: DMSO:27.5 mg/mL (40.05 mM)

Bioactivity

• In Vivo:
  Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight. Haematoxylin and eosin tissue staining and blood biochemical examinations revealed no significant adverse effects following the two LSKL peptide administrations. In the clinical setting, plasma TSP-1 levels were lowest on the first day after hepatectomy. However, plasma TSP-1 levels at this stage were significantly higher in patients with subsequent liver dysfunction compared with levels in those without liver dysfunction following hepatectomy
  Read more...
• Animal Research:
  Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

LSKL, Inhibitor of Thrombospondin TSP 1 acetate, LSKL, Inhibitor of Thrombospondin TSP1 acetate, LSKL, Inhibitor of Thrombospondin TSP-1 Acetate, Smad, TGF-b/Smad, TGFb, TGFbeta/Smad, TGF-beta, TGFbeta, TGF-β/Smad, TGFβ

Compound Identifiers

PubChem CID

172005545